company background image
RVX logo

Resverlogix TSX:RVX Stock Report

Last Price

CA$0.055

Market Cap

CA$15.1m

7D

0%

1Y

-62.1%

Updated

28 Mar, 2024

Data

Company Financials

RVX Stock Overview

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs.

RVX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Resverlogix Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Resverlogix
Historical stock prices
Current Share PriceCA$0.055
52 Week HighCA$0.26
52 Week LowCA$0.055
Beta0.78
1 Month Change-8.33%
3 Month Change-21.43%
1 Year Change-62.07%
3 Year Change-93.53%
5 Year Change-98.39%
Change since IPO-96.45%

Recent News & Updates

Recent updates

How Much Of Resverlogix Corp. (TSE:RVX) Do Institutions Own?

Dec 11
How Much Of Resverlogix Corp. (TSE:RVX) Do Institutions Own?

Shareholder Returns

RVXCA BiotechsCA Market
7D0%1.4%0.4%
1Y-62.1%-26.0%9.0%

Return vs Industry: RVX underperformed the Canadian Biotechs industry which returned -26% over the past year.

Return vs Market: RVX underperformed the Canadian Market which returned 9% over the past year.

Price Volatility

Is RVX's price volatile compared to industry and market?
RVX volatility
RVX Average Weekly Movement12.7%
Biotechs Industry Average Movement12.4%
Market Average Movement8.5%
10% most volatile stocks in CA Market18.4%
10% least volatile stocks in CA Market3.1%

Stable Share Price: RVX's share price has been volatile over the past 3 months.

Volatility Over Time: RVX's weekly volatility (13%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200119Don McCaffreyhttps://www.resverlogix.com

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications.

Resverlogix Corp. Fundamentals Summary

How do Resverlogix's earnings and revenue compare to its market cap?
RVX fundamental statistics
Market capCA$15.10m
Earnings (TTM)-CA$17.36m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RVX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$12.82m
Earnings-US$12.82m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.047
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-97.4%

How did RVX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.